Conference programme

Please download the BCH 2025 scientific program here
Please download the BCH for nurses scientific program here

24th April
14:00-15:00Registration, Hilton Tallinn Park Hotel (F.R. Kreutzwaldi 23)
15:00-15:05Opening of the Conference
15:05-16:30Scientific Session I: Migration and Medicine
15:05-15:30„Migration medicine” - Kristiina Tambets (tbc), Estonia
15:30-15:50 „Epidemiology” - Galina Opikova, Estonia
15:50-16:10 „Help for Ukrainian Hematology Patients in Vilnius University Hospital Santaros Klinikos“ - Milda Mikalonytė, Lithuania
16:10-16:30 „Impact of climate changes on infections“ - Bruno Saar, Estonia
16:30-17:00Coffee break, exhibition
17:00-18:45Scientific session II: Bleeding disorders
17:00-17:40„Why may patients with von Willebrand disease bleed?“ - Jecko Thachil, UK
17:40-18:00 „Overview and results of the von Willebrand disease genotype and phenotype study“ - Sonata Šaulytė Trakymienė, Lithuania
18:00-18:15 „Diagnostic algorithm for von Willebrand disease“ - Marika Pikta, Estonia
18:15-18:30 „The Situation of Laboratory Diagnostics of Bleeding Disorders in Baltic States“ - Valdas Banys, Lithuania
18:30-18:45 „Management of mild/moderate hemophilia patient with atrial fibrillation and dilatative cardiomyopathy" - Kristīne Bernāte, Latvia
19:00Networking event (foyer area of the venue, no live music/entertainment)

25th April
07:00-08:15Fun & Run at Kadriorg Park (gathering at Hilton Tallinn Park Hotel reception foyer). Organized by DMC Conference Expert in coopertion with Tallinn Convention Bureau)
09:00-11:00Scientific Session III: Malignant lymphomas
09:00-09:30 „Current and Emerging Treatments for Relapsed or Refractory Large B-cell Lymphoma" - Prof. Frederik Damm, Germany
09:30-09:45 „Polatuzumab vedotin with chemotherapy as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas: VUL SK experience“ - Tautvilė Smalinskaitė, Lithuania
09:45-10:00 „Epcoritamab in relapsed or refractory large B-cell lymphomas: Estonian experience“ - Renate Katsev, Estonia
10:00-10:15 „Early Clinical Efficacy of Place-of-Care Manufactured MB-CART19.1 Cell Therapy in Patients with Relapsed or Refractory CD19+ Lymphomas in a Real-World Setting, VUL SK” - Skirmantė Černauskienė, Lithuania
10:15-10:45 „Paradigm Shifts in Hodgkin Lymphoma Treatment" - Peter Borchmann, Germany
10:15-10:45 „Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma before autologous stem cell transplantation: VUL SK experience“ - Lukas Kevličius, Lithuania
11:00-11:30Coffee break, exhibition
11:30-13:00Scientific session IV: Acute Myeloid Leukeemia
11:30-12:00Keynote lecture - „Management of acute myeloid leukaemia in 2024“ - Andrius Žučenka, Lithuania
12:00-12:20 „Lithuanian experience - Individualized therapy for R/R AML in Vilnius“ - Andrius Žučenka, Lithuania
12:20-12:40 „Hematopoietic stem cell transplantation in children with AML – Estonian experience“ - Triin Pohlak, Estonia
12:40-13:00 „Modern strategies in AML treatment: the role of CPX-351 and Latvian insights" - Arturs Uzars, Latvia
13:00-14:00Lunch
13:00-14:00Roche satellite session on Malignant Lymphomas: „The role of bispecifics in third line treatment for diffuse large B-cell lymphoma with focus on Columvi® (glofitamab)" - Frederik Damm, Germany
14:00-17:50Scientific session V: Acute lymphoblastic leukeemia
14:00-14:30 Lecture „Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia“ - Anita Rijneveld, Netherlands
14:30-14:50 „Lithuanian experience of treatment with blinatumomab“ - Goda Vaitkevičienė, Lithuania
14:50-15:10 „Estonian experience of treatment with blinatumomab ” - Maarja Karu, Estonia
15:10-15:30 „Early Clinical Efficacy of Place-of-Care Manufactured MB-CART19.1 Cell Therapy in Patients with Relapsed or Refractory CD19+ ALL in a Real-World Setting, VUL SK” - Skirmantė Černauskienė, Lithuania
15:30-16:00Coffee break, exhibition
16:00-17:50Scientific session VI: Multiple Myeloma
16:00-16:30„Plasmacell disorders - precursor conditions: MGUS, SMM, iStopMM” - Sigrun Thorsteinsdottir, Iceland
16:30-16:50 „MRD driven treatment in MM or RRMM treatment” - Fredrik Schjesvold, Norway
16:50-17:10 „NORASCT in Lithuania and Estonia” - Vilmantė Vaitekėnaitė, Lithuania and Diana Loigom, Estonia
17:10-17:30 „Carfilzomib, lenalidomide, and dexamethasone Induction and consolidation with salvage autologous stem cell transplantation. Single centre experience“ - Vilmantė Vaitekėnaitė, Lithuania
17:30-17:50 „Bispecific T-cell redirectors“ - Diana Loigom, Estonia
19:30Conference dinner in Cruise Terminal of Tallinn Old City Harbour, Logi Str 4 (a surcharge applies)

26th April
09:00-10:30Scientific Session VII: Myeloproliferative Neoplasms
09:00-09:40 „Risk assessment of MPN and management of high risk PV“- Prof. Heinz Gisslinger, Austria
09:40-10:15 „Advances in myelofibrosis treatment“ - Tomasz Sacha, Poland
10:15-10:30 „Latvian experience - PV treatment with ropeginterferon alfa-2b“ - Dārta Balode, Latvia
10:30-10:45 „Overview of MPN management in Estonia“ - Halliki Kõdar, Estonia
10:45-11:00Coffee break, exhibition
11:00-12:15AstraZeneca satellite symposia - "Beyond the Blood: Exploring treatment approaches in CLL and PNH"
11:00-11:30 „Messages from specialist: complement dysregulation in hematological diseases - what's on stake?" - Andrius Degulis, Edita Gasiūnienė, Lithuania
11:30-12:00 „CLL treatment landscape“ - Clemence Wendtner, Germany
12:00-12:15 Discussion panel „Where are the Baltics in terms of CLL and PNH, what to improve“ - Iige Viigimaa, Estonia, Andrius Degulis, Lithuania
12:15-13:00Scientific session VIII
12:15-13:00Rapid fire. Short presentations/ case studies from Baltic States
13:00-13:30 Lecture by Estonian leukaemia and lymphoma patients’ organization
13:30Final remarks, conference closing session